June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Neuroprotective properties of collagen mimetic peptides
Author Affiliations & Notes
  • Robert O. Baratta, MD
    Research, Stuart Therapeutics, Inc, Stuart, Florida, United States
  • Brian J. Del Buono
    Research, Stuart Therapeutics, Inc, Stuart, Florida, United States
  • Silvia Pasini
    Ophthalmology, Vanderbilt Eye Institute, Nashville, Tennessee, United States
  • Eric Schlumpf
    Research, Stuart Therapeutics, Inc, Stuart, Florida, United States
  • David J Calkins
    Ophthalmology, Vanderbilt Eye Institute, Nashville, Tennessee, United States
    Research, Stuart Therapeutics, Inc, Stuart, Florida, United States
  • Footnotes
    Commercial Relationships   Robert Baratta, MD, Stuart Therapeutics, Inc (I), Stuart Therapeutics, Inc (E), Stuart Therapeutics, Inc (P); Brian Del Buono, Stuart Therapeutics, Inc (E), Stuart Therapeutics, Inc (I), Stuart Therapeutics, Inc (P); Silvia Pasini, None; Eric Schlumpf, Stuart Therapeutics, Inc (I), Stuart Therapeutics, Inc (E), Stuart Therapeutics, Inc (P); David Calkins, Stuart Therapeutics, Inc (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2352. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert O. Baratta, MD, Brian J. Del Buono, Silvia Pasini, Eric Schlumpf, David J Calkins; Neuroprotective properties of collagen mimetic peptides. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2352.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Extracellular matrix in the central nervous system comprises a complex macromolecular combination of proteins and polysaccharides that provides a substrate for maintenance of neurons and their axons. Glaucoma and other optic neuropathies involve degradation of the extracellular matrix in the retina and optic nerve head, through which unmyelinated retinal ganglion cell axons pass in forming the optic nerve proper. This degradation also affects collagen fibers, which are a major constituent of the matrix. Here we tested whether collagen mimetic peptides (CMPs), which repair damaged collagen, promote (1) survival and neurite outgrowth of neurons in vitro stressed by collagen degradation and (2) ganglion cell axon function in an inducible mouse model of glaucoma.

Methods : For in vitro studies, we compared neurite outgrowth of dorsal root ganglion cells (DRGs) plated on partially digested type 1 collagen and treated either with CMP or vehicle. For in vivo testing of efficacy, we elevated ocular pressure unilaterally in mice using microbead occlusion and measured anterograde axonal transport of cholera toxin B to the superior colliculus following topical CMP treatment vs. vehicle.

Results : In vitro, DRG neurons on damaged collagen treated with CMP demonstrated increased dendritic field area (p≤0.03) and neurite length (p≤0.02) compared to untreated, while neurite length in treated collagen also exceeded by 70% length in naïve collagen (p=0.002). In vivo, following three weeks of elevated ocular pressure (+35%), treatment with CMP’s significantly protected axon transport vs untreated (p<0.01).

Conclusions : Our results emphasize the critical role intact collagen plays in maintaining ECM and neuronal function. CMPs offer therapeutic potential for use in neuroprotective or reparative regimens designed to promote neurite growth and axon function in glaucoma and other optic neuropathies

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×